TACT2

Trial to Assess Chelation Therapy 2

ClinicalTrials.gov: NCT02733185

Patient Population:

  • 1,200 post-MI patients with diabetes
  • 50 yrs or older
  • History of diabetes and myocardial infarction

Trial Design: Double-blind, randomized

Intervention: EDTA chelation therapy versus placebo in individuals with coronary artery disease and diabetes

Primary Endpoint: A composite of all-cause mortality, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina

Sponsors: NIH, NHLBI, NCCIH

Economic Substudy

Principal Investigator:

Daniel B. Mark, MD

TACT2: ECONOMIC STUDY

Daniel Mark, MD presents the results of the quality of life substudy in the Trial to Assess Chelation Therapy.

Overview

The specific aim of the economic substudy of the Trial to Assess Chelation Therapy 2 is to perform an economic analysis including a cost-effectiveness assessment of the TACT2 chelation strategy.

Trial is enrolling.

See study website for more information.

TACT2 Publications